Results 61 to 70 of about 104,914 (293)

Characteristics and survival of patients with advanced cancer and p53 mutations. [PDF]

, 2014
P53 mutations are associated with invasive tumors in mouse models. We assessed the p53mutations and survival in patients with advanced cancer treated in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations.
Aldape, Kenneth, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Palmer, Gary A, Said, Rabih, Thomas, Christoforos, Tsimberidou, Apostolia M, Wheler, Jennifer J, Ye, Yang   +12 more
core   +9 more sources

The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications

Journal of Pharmaceutical Policy and Practice, 2017
When patients are told that standard medical treatment options have been exhausted, their treating physicians may start looking for promising new drugs that are not yet approved, and still under investigation.
Eline M. Bunnik, Nikkie Aarts, Suzanne van de Vathorst   +2 more
doaj   +1 more source

A Research Documentation On Men's Sexual Health Disclosed [PDF]

, 2010
When VigRX Plus was surveyed by Vedic Life-Sciences in proved to be the best pill treatment for sexual health.

core  

Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis [PDF]

, 2018
Objective: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107 ...
Achuthan, Akagawa, Aletaha, Aletaha, Antoniu, Avci, Berghen, Borg, Borie, Brown, Buch, Burmester, Burmester, Calisto, Cella, Chen, Cook, Cornish, Cottin, Crotti, Dawson, Felson, Fleetwood, Fries, Greven, Guo, Hamilton, Jaguin, Kelly, Khan, Lazaro, Listing, Minter, Prevoo, Shaw, Shibata, Singh, Tsuchiya, Van der Heijde, Van Gestel, Van Onna, Ware, Weinblatt, Yoshida, Zhan   +44 more
core   +1 more source

Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia

Advanced Science, EarlyView.
A continuous, multi‐domain characterization of cognitive decline across the Alzheimer's disease spectrum identifies when individual cognitive measures become abnormal. Episodic memory declines first, followed by executive function, language, processing speed, and visuospatial abilities, supporting improved clinical interpretation and optimized endpoint
Fredrik Öhman, Lars Lau Raket, Michael Schöll, for the Alzheimer's Disease Neuroimaging Initiative†   +3 more
wiley   +1 more source

Levosimendan na insuficiência cardíaca descompensada: revisão sistemática e metanálise Levosimendan in acute decompensated heart failure: systematic review and meta-analysis

Arquivos Brasileiros de Cardiologia, 2010
FUNDAMENTO: A insuficiência cardíaca descompensada (ICD) é uma condição bastante prevalente e com alta mortalidade. O levosimendan está entre as novas drogas que têm sido testadas para o seu manejo.
Rodrigo Antonini Ribeiro, Luis Eduardo Paim Rohde, Carisi Anne Polanczyk   +2 more
doaj  

TB and HIV Therapeutics: Pharmacology Research Priorities

AIDS Research and Treatment, 2012
An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co-infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard ...
Kelly E. Dooley, Peter S. Kim, Sharon D. Williams, Richard Hafner   +3 more
doaj   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source